WallStreetZenWallStreetZen

NASDAQ: HUMA
Humacyte Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for HUMA

Based on 4 analysts offering 12 month price targets for Humacyte Inc.
Min Forecast
$4.00-24.1%
Avg Forecast
$9.25+75.52%
Max Forecast
$15.00+184.63%

Should I buy or sell HUMA stock?

Based on 4 analysts offering ratings for Humacyte Inc.
Strong Buy
Strong Buy
3 analysts 75%
Buy
0 analysts 0%
Hold
1 analysts 25%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their HUMA stock forecasts and price targets.

HUMA stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
lockedlocked$00.00+00.00%2024-09-05
lockedlocked$00.00+00.00%2024-07-15Find Out Why
lockedlocked$00.00+00.00%2024-07-02
lockedlocked$00.00+00.00%2024-03-26

1 of 1

Forecast return on equity

Is HUMA forecast to generate an efficient return?
Company
-25.32%
Industry
-388.9%
Market
58.96%
HUMA's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is HUMA forecast to generate an efficient return on assets?
Company
5.18%
Industry
27.36%
HUMA is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

HUMA earnings per share forecast

What is HUMA's earnings per share in the next 3 years based on estimates from 4 analysts?
Avg 1 year Forecast
-$1.09
Avg 2 year Forecast
-$0.73
Avg 3 year Forecast
-$0.40

HUMA revenue forecast

What is HUMA's revenue in the next 3 years based on estimates from 1 analyst?
Avg 1 year Forecast
$2.4M
Avg 2 year Forecast
$7.0M
Avg 3 year Forecast
$83.1M

HUMA vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
HUMA$5.27$9.25+75.52%Strong Buy
ADPT$4.27$5.50+28.81%Strong Buy
ATXS$11.12$25.20+126.62%Strong Buy
EXAI$4.90$6.00+22.45%Hold
WVE$5.13$13.17+156.67%Strong Buy
View Top Biotech Stocks

Humacyte Stock Forecast FAQ

Is Humacyte Stock a good buy in 2024, according to Wall Street analysts?

The consensus among 4 Wall Street analysts covering (NASDAQ: HUMA) stock is to Strong Buy HUMA stock.

Out of 4 analysts, 3 (75%) are recommending HUMA as a Strong Buy, 0 (0%) are recommending HUMA as a Buy, 1 (25%) are recommending HUMA as a Hold, 0 (0%) are recommending HUMA as a Sell, and 0 (0%) are recommending HUMA as a Strong Sell.

If you're new to stock investing, here's how to buy Humacyte stock.

What is HUMA's earnings growth forecast for 2024-2026?

(NASDAQ: HUMA) Humacyte's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 15.32%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 17.02%.

Humacyte's earnings in 2024 is -$139,660,000.On average, 4 Wall Street analysts forecast HUMA's earnings for 2024 to be -$129,495,967, with the lowest HUMA earnings forecast at -$146,801,880, and the highest HUMA earnings forecast at -$108,609,521. On average, 3 Wall Street analysts forecast HUMA's earnings for 2025 to be -$87,520,178, with the lowest HUMA earnings forecast at -$101,448,454, and the highest HUMA earnings forecast at -$76,384,718.

In 2026, HUMA is forecast to generate -$47,143,693 in earnings, with the lowest earnings forecast at -$51,320,982 and the highest earnings forecast at -$42,966,404.

What is HUMA's revenue growth forecast for 2024-2026?

(NASDAQ: HUMA) Humacyte's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 34.96%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.31%.

Humacyte's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast HUMA's revenue for 2024 to be $291,216,738, with the lowest HUMA revenue forecast at $291,216,738, and the highest HUMA revenue forecast at $291,216,738. On average, 1 Wall Street analysts forecast HUMA's revenue for 2025 to be $839,038,388, with the lowest HUMA revenue forecast at $839,038,388, and the highest HUMA revenue forecast at $839,038,388.

In 2026, HUMA is forecast to generate $9,921,658,772 in revenue, with the lowest revenue forecast at $9,921,658,772 and the highest revenue forecast at $9,921,658,772.

What is HUMA's forecast return on assets (ROA) for 2024-2027?

(NASDAQ: HUMA) forecast ROA is 5.18%, which is lower than the forecast US Biotechnology industry average of 27.36%.

What is HUMA's Price Target?

According to 4 Wall Street analysts that have issued a 1 year HUMA price target, the average HUMA price target is $9.25, with the highest HUMA stock price forecast at $15.00 and the lowest HUMA stock price forecast at $4.00.

On average, Wall Street analysts predict that Humacyte's share price could reach $9.25 by Sep 5, 2025. The average Humacyte stock price prediction forecasts a potential upside of 75.52% from the current HUMA share price of $5.27.

What is HUMA's Earnings Per Share (EPS) forecast for 2024-2026?

(NASDAQ: HUMA) Humacyte's current Earnings Per Share (EPS) is -$1.26. On average, analysts forecast that HUMA's EPS will be -$1.09 for 2024, with the lowest EPS forecast at -$1.23, and the highest EPS forecast at -$0.91. On average, analysts forecast that HUMA's EPS will be -$0.73 for 2025, with the lowest EPS forecast at -$0.85, and the highest EPS forecast at -$0.64. In 2026, HUMA's EPS is forecast to hit -$0.40 (min: -$0.43, max: -$0.36).

What is HUMA's forecast return on equity (ROE) for 2024-2027?

(NASDAQ: HUMA) forecast ROE is -25.32%, which is considered weak.
©2024 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.